@LungCancerRx

✍️ Prescribing empowerment, knowledge & hope in #lungcancer | 🤝 Team @adesaimd @fawziaburous @lungoncdoc | 🫶 #lcsm #ASCO26

#lcsm
Joined May 2023
NEW episode of #LungCancerRx is out! Expert guest @FSkoulidis breaks down KRAS, STK11, and KEAP1 mutant NSCLC. @ADesaiMD @FawziAbuRous @lungoncdoc @OncNewsCentral oncologynewscentral.com/vide…
5
6
958
LungCancerRx 🫁💊 retweeted
SigVie-002 #ESMO26 (negative): sigvotatug vedotin (IB6 ADC) vs docetaxel, pretreated nsq NSCLC ➡️ mOS 11.9 vs 11.5 mo, HR 0.929 ➡️ mPFS 4.7 vs 4.2 mo, HR 0.844 ➡️ Post hoc 2L: OS HR 0.831, PFS HR 0.795 Why is docetaxel so hard to beat? @LungCancerRx @OncoAlert @oncodaily
2
3
194
LungCancerRx 🫁💊 retweeted
OptiTROP-Lung04 final OS #ESMO26: sac-TMT vs platinum-pem post EGFR-TKI, EGFRm NSCLC ➡️ mOS 25.9 vs 17.4 mo, HR 0.69 ➡️ 2-yr OS 54.1 vs 37.2% ➡️ 22.6% of chemo arm later got an ADC; RPSFT HR 0.57 ADC or chemo first after EGFR-TKI? @LungCancerRx @OncoAlert @oncodaily
2
1
166
LungCancerRx 🫁💊 retweeted
Krascendo 1 #ESMO26: divarasib vs sotorasib/adagrasib, pretreated KRAS G12C NSCLC ➡️ mPFS 9.8 vs 5.7 mo, HR 0.58 ➡️ mOS 17.7 vs 12.0 mo, HR 0.56 ➡️ ORR 58 vs 32% ➡️ G3-4 TRAEs 24.6 vs 34.5%; diarrhea 66 vs 38% Where does first-gen G12C fit? @LungCancerRx @OncoAlert @oncodaily
2
5
244
LungCancerRx 🫁💊 retweeted
SAFFRON #ESMO26: osi+savo vs platinum-pem post-osimertinib, EGFRm MET OE/amp NSCLC ➡️ mPFS 7.6 vs 5.4 mo, HR 0.55 ➡️ mOS 17.8 vs 12.9 mo, HR 0.68 ➡️ ORR 51 vs 27% ➡️ G≥3 TRAEs 40 vs 52%; edema 49% Who gets a MET re-biopsy after osimertinib? @LungCancerRx @OncoAlert @oncodaily
1
4
268
LungCancerRx 🫁💊 retweeted
🚨Hot off the press! In #SCLC, tarlatamab plus durvalumab in 1L ES-SCLC shows OS improvement! Looking forward to the full data! @LungCancerRx
2
32
1
54
4,649
LungCancerRx 🫁💊 retweeted
Almost time for the #ASCO26 plenary session!! Lung cancer research is BACK on the center stage after a (brief) hiatus last year! Can’t wait to unpack the data in real time!! @ASCO – at Chicago, IL
1
7
25
1,890
LungCancerRx 🫁💊 retweeted
🫁 OptiTROP-Lung05: sac-TMT + pembrolizumab vs pembrolizumab in PD-L1+ 1L NSCLC (phase III, n=413) #ASCO26 🎯 Significant PFS improvement (HR 0.35 by BICR) 💥ORR: 70.2% vs 42.0% (+28.3%) 🔥 Deep responses: 49.0% vs 25.9% ▪️Favorable early OS trend (HR 0.55) An impressive TROP-ic storm for PFS…but will it weather the ultimate OS forecast? And outperform chemo + pembro? The final chapter is still unwritten 🤔 #ASCO26 @OncoAlert @OncoReporte @StephenVLiu @ASCO @_SEOM @LungCancerRx @Lung_Cancers @lungoncdoc
8
19
1,456
LungCancerRx 🫁💊 retweeted
🫁 D3S-001: first-line elisrasib ± pembrolizumab in KRAS G12C-mutant NSCLC #ASCO26 🎯 Elisrasib monotherapy: ORR 78.0%, mPFS 12.4 months, 12-month OS 90% 💥 Elisrasib + pembrolizumab: ORR 81.3%, mPFS not reached, 12-month OS 88.8% ⚡ Responses were rapid, with most responders achieving response by week 6 🚨 Higher grade ≥3 TRAEs with the combination (32.7%) The response rates are elis-rising…now we wait to see whether phase III data can truly KRAS the finish line 😉 #ASCO26 @OncoAlert @OncoReporte @ASCO @_SEOM @LungCancerRx @Lung_Cancers
11
18
1,175
LungCancerRx 🫁💊 retweeted
At #ASCO26, I’m excited to moderate the LungSphere🫁 Leadership Exchange in Chicago. What are you hoping to take away this year? • Inspiration for your practice 🩺 • Peer connection 💬 • Motivation and fresh perspective 💡 Mentorship and leadership are at the core of how we grow and how we elevate cancer care together. Join us for an evening of meaningful conversation, shared insights, and community. 📅 June 1 | 6:30–8 PM CT 📍 Fairmont ChicagoRegister: astrazenecaevents.com/nWdYMr #ASCO26 #LungSphere #Mentorship #Leadership #Oncology @ASCOPost @ASCOPres @LUNGevity @lungoncdoc @RManochakian @ASridharMD @AnaVManana @OncodailyLung @LungCAN @Lung_Cancers @OncBrothers @OncoAlert @OncLive
4
11
755
LungCancerRx 🫁💊 retweeted
‼️ Phase 3 WU-KONG28: 1L Sunvozertinib v Chemotherapy in EGFR exon20 NSCLC ▫️mPFS 10.3 v 7.5 mos (HR 0.65) ▫️ORR ~60% v 30% Keep in mind, 1L PAPILLON (Amivantamab + chemo) is currently our SOC (mPFS 11.4 mos, ORR of 73%) #ASCO26 @ASCO
Presented at #ASCO26: In NSCLC with 𝘌𝘎𝘍𝘙 exon 20 insertions, first-line sunvozertinib led to longer progression-free survival than chemotherapy. The most common adverse events of grade 3 or higher were elevated creatine kinase, diarrhea, and anemia. Full phase 3 WU-KONG28 trial results: nej.md/4fQWMwa @ASCO
4
26
2
44
8,054
LungCancerRx 🫁💊 retweeted
Early on, I was told patient education in oncology ‘isn’t physician work.’ I disagreed. Invested anyway. With mentors, patient advocates & @cancerGRACE. Never imagined being named Patient Educator of the Year in Cancer Care. Education is empowerment. Truly grateful. #ASCO26 – at Chicago, IL
29
20
4
162
13,364
LungCancerRx 🫁💊 retweeted
Our first of MANY selfies to come! Looking forward to seeing and creating with all my #SoMe friends on 5/29!
1
2
16
803
LungCancerRx 🫁💊 retweeted
Okay! There… I fixed it. I keep saying it… AI is not always accurate/up to date! Can’t wait to kick start #ASCO26 with this board review. Registration is closed (this got filled quickly). #OncTwitter #MedTwitter @TwoOncDocs @OncUpdates
1 day until Clinicals to Exam 🌟 pre #ASCO26 From 1-5PM, we will cover a high yield overview of: Board Prep 101 Breast CA Lung CA CRC Pancreatic CA Testicular CA Prostate CA Genetics & Biomarkers & new this year a special panel Life After Fellowship inc @JenSchwartzIUSM
6
8
23
3,377
LungCancerRx 🫁💊 retweeted
I second this 👏🏽 Want to find the thoracic oncologists at #ASCO26 this afternoon? Here’s where we’ll be: ▫️AGAs: Updates in EGFR, ALK, and RET ▫️Non-AGAs: Novel frontline combinations with checkpoint inhibitors @ASCO
#ASCO26 opens at 1:00 PM CT and thoracic is first out. ORAL: Lung Cancer—NSCLC Metastatic, Hall D2, livestreamed. The opening read on where metastatic NSCLC moves this year. If you treat lung, this is your room. #ASCO26 @OncoAlert @OncBrothers @StephenVLiu @Jani_Chinmay @asco @myESMO @glopesmd @SylvesterCancer @latinamd @iaslc @COlazagasti @openevidence @openmedicinehq
4
12
1,137
LungCancerRx 🫁💊 retweeted
🚨📣Inviting colleagues @ASCO #ASCO26 to: ✅An #EducationSession, I’m honored to chair & speak at, joined by great experts/colleagues: Drs @NReguart & Hegi-Johnson. ⭐️Title: It’s 2026. #Updates in #SmallCell #LungCancer-No Longer Too Small to Ignore. ⏰Sun, May 31st at 8:00 📍Room E451
5
16
1
50
10,135
LungCancerRx 🫁💊 retweeted
🔥@ASCO #ASCO26 Starts TODAY. This year’s @ASCOPres theme: ⭐️The #Science & Practice of #Translation: Improving #Cancer Outcomes #Worldwide. Reminder of ULTIMATE #Goal: ✅Applying & Translating GREAT #Research & GREAT #Knowledge to HELP #Patients with #Cancer #Everywhere.
10
28
856
LungCancerRx 🫁💊 retweeted
⭐️ABSTRACT 8052: NIBIT-EPI-MESO study ❓Can methylation profiling identify which pts with malignant pleural mesothelioma (MPM) may respond favorably to immunotherapy? 1⃣Unsupervised methylation profiling of 83 samples identified four MPM subsets: (1) Demethylated (DEM), (2) Low, (3) Intermediate (INT), and (4) CpG island methylator phenotype (CIMP). 2⃣LOW/DEM methylation subtypes were enriched among responder (R) pts and INT/CIMP were enriched among non-responders (p =0.002) 3⃣Most fascinating (to me) was no association with histologic subtype (p=0.33). Based on Checkmate-743 [image below] would have expected sarcomatoid subtype to be heavily susceptible to a response. 4⃣Few key limitations: - Retrospective - Small functional TME subset (n=35) - Mixed ICI regimens (anti–CTLA-4 ± PD-1/PD-L1) complicate attribution of response 📋KEY POINT: I LOVE the idea of using immune-based classifiers (in this case methylation based) to develop strategies to determine who will benefit with ICI among patients with MPM (9/13) 🔗Checkmate-743: pubmed.ncbi.nlm.nih.gov/3348… @lcsmchat @OncoAlert @OncLive @Lung_Cancers @Onco_Nexus @LungCancerRx @LungCancerEu @MedwatchKate
1
2
6
666
LungCancerRx 🫁💊 retweeted
⭐️ABSTRACT 8010: Air Pollution and Risk of Lung Cancer 📔The seminal 2023 @Nature paper showed a significant association in environmental particulate matter measuring ≤2.5 μm (PM2.5) and risk for #EGFR #NSCLC. 1⃣This large NCDB analysis (>1 million pts) suggests chronic PM₂.₅ exposure is associated with more advanced lung cancer findings 2⃣Key findings: - Each standard deviation increase in PM₂.₅ → ~5% higher odds of stage III/IV disease -In multipollutant models, PM₂.₅ remained significant (OR = 1.062, 95% CI: 1.047–1.076; p , 0.001), with combined pollution burden linked to a 3.1% increase in odds (95% CI: 1.5–4.7%; p , 0.001). 3⃣Caveats: -The study cannot distinguish if air pollution accelerates tumor progression (plausible) OR if air pollution here is linked with other determinants of care (smoking prevalence, occupational exposure, health care access) -No smoking pack year data? I understand the problems and recall biases associated with getting smoking level data, but seems like it would be important. -Ecologic exposure fallacy (county-level pollution ≠ individual exposure or risk) 📋KEY POINT: Emerging and ongoing population level data suggests link between air pollution and lung cancer risk. 😡RANT: We need more investment into these type of studies, to truly parse out these signals. This can only happen with funding. Sadly we are lacking vision, competence, and expertise from our elected officials and from our health care administration. (12/13) @lcsmchat @OncoAlert @OncLive @Lung_Cancers @Onco_Nexus @LungCancerRx @LungCancerEu @MedwatchKate @YoungLungCancer @DrCatharineY
1
14
2
30
4,301